Clinical trials: Neutropenia, Febrile, open to volunteers
Multiple Myeloma
The Ambient Light Multiple Myeloma Study
The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients…
- Trial name
- NCT05737732
- Testing
- Circadian Effective Lighting, Circadian Ineffective Lightning (CIL)
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
C15.378
Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients.
The combination of amoxicillin-clavulanate (AC) and a fluoroquinolone (FQ) is currently recommended for the treatment for outpatients with hematologic malignancies presenting with chemotherapy-induced fever (CIF), if the expected…
- Trial name
- AC-CIF (NCT07483736)
- Testing
- amoxicillin-clavulanate, Amoxicillin-clavulanate ciprofloxacin
- Where
- 16 sites in France
- Volunteers
- 1,526 people
- Sponsor
- Versailles Hospital
Febrile Neutropenia, Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy
Comparison of G-CSF & Antibiotics Versus Antibiotics Alone in Resolution of Febrile Neutropenia
This study aim to find the best option for children having cancer who develop low immunity state due to chemotherapy
- Conditions
- Febrile Neutropenia, Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy, Febrile Neutropenia, Drug-Induced, G-CSF
- Trial name
- AGF-FN (NCT06988826)
- Testing
- G-CSF, Antibiotics only
- Volunteers
- 150 people
- Sponsor
- King Edward Medical University
Febrile Neutropenia (FN), Pediatric Cancer
Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia
The goal of this clinical trial is to evaluate whether stopping antibiotic treatment early is safe in paediatric patients with cancer who develop high-risk febrile neutropenia but show good clinical evolution and low biomarker…
- Conditions
- Febrile Neutropenia (FN), Pediatric Cancer, Hematologic Malignancies, Solid Tumors
- Trial name
- E-STOP2 (NCT07590648)
- Testing
- Early Discontinuation of Antibiotics, Standard Antibiotic Continuation Strategy
- Where
- 4 sites in Spain
- Volunteers
- 136 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Malignant Tumor
Study on the Efficacy and Safety of Different Doses of PEG-rhG-CSF for Primary Prevention of Febrile Neutropenia
In a prospective, multicenter, real-world setting, the efficacy and safety of 3mg low-dose pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in the primary prevention of febrile neutropenia (FN)…
- Trial name
- NCT07829276
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Zhejiang Provincial People's Hospital
Febrile Neutropenia, Sarcoma
Acupuncture as add-on to G-CSF for Febrile Neutropenia-related Hospitalization in Doxorubicin-treated Patients With Sarcoma
Chemotherapy-induced febrile neutropenia (CIFN) is a dangerous complication of many chemotherapy drugs, with current treatment with granulocyte colony-stimulating factors (G-CSFs) accompanied by adverse effects, primarily muscle…
- Conditions
- Febrile Neutropenia, Sarcoma, Doxorubicin Adverse Reaction, Hospitalization-Associated Infection
- Trial name
- NCT06500715
- Testing
- Acupuncture
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Shaare Zedek Medical Center
Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM)
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy
The purpose of the CARMic study is to investigate whether a restrictive, microbiome-sparing antibiotic strategy can better preserve the gut microbiota in patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy…
- Conditions
- Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM), Gut Microbiota
- Trial name
- CARMic (NCT07842198)
- Testing
- ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Zealand University Hospital
Hematologic Malignancy, Febrile Neutropenia
Early Neutropenic Fever De-escalation of Antibiotics Study
This is a randomized, open label clinical trial among individuals with hematologic conditions. The trial aims to evaluate the safety and clinical outcomes of de-escalating antibiotic therapy among stable individuals diagnosed…
- Conditions
- Hematologic Malignancy, Febrile Neutropenia, Antibiotic Stewardship
- Trial name
- END (NCT06278896)
- Testing
- Cessation of antibiotics
- Volunteers
- 260 people
- Sponsor
- Brigham and Women's Hospital
Oncology, Periodontitis
PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications
The aim of this feasibility trial is to determine if it is safe and feasible to treat oral health diseases in people with haematological cancers before they start their chemotherapy to reduce complications and disruption to…
- Conditions
- Oncology, Periodontitis, Myeloma, Oral Mucositis
- Trial name
- NCT06450821
- Testing
- PRIOR [Proactive Intensive Oral Review & Treatment]
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Leeds
Febrile Neutropenia
Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.
This single-arm, open-label clinical study evaluates the efficacy and safety of a standardized empirical anti-infective escalation protocol for patients with hematological malignancies complicated by febrile neutropenia.
- Trial name
- NCT07204522
- Testing
- Carbapenems, Anti-Gram-positive agent, Antifungal agent
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanxi Bethune Hospital
Febrile Neutropenia
Next-Generation-Sequencing Approach to Neutropenic Sepsis
The aim of this prospective, observational, non-interventional, multi-centre study of the diagnostic use of DISQVER in neutropenic patients with FN is to provide further evidence of the efficacy of an NGS-based approach for…
- Trial name
- NEXUS (NCT05815628)
- Testing
- DISQVER
- Where
- 6 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Boris Böll
Safety Issues
Early De-escalation of Empirical Antibiotics Treatment for Neutropenic Fever
This is a randomized study to evaluate the safety and feasibility of early de-escalation of empirical antibiotics treatment in neutropenic fever patients undergoing hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT04270786
- Testing
- Early de-escalation, Standard
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Neutropenic Fever
Antibiotic Stewardship in Suspected Neutropenic Fever (ASTERIC Trial)
Executive Summary Background: Neutropenic Fever (NF), or febrile neutropenia, occurs in patients with early stage and metastatic solid tumours, non-leukaemic haematological cancers and acute leukaemia.
- Trial name
- NCT06794320
- Testing
- NF Protocol, ASTERIC protocol
- Where
- Hong Kong
- Volunteers
- 648 people
- Sponsor
- The University of Hong Kong
Febrile Neutropenia
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens
The study proposes a planned, double-blind, non-inferiority clinical trial involving patients with febrile neutropenia and risk of extended-spectrum beta-lactamase (ESBL) infection.
- Trial name
- CLEMENT (NCT06342115)
- Testing
- Ceftolozane-Tazobactam, Meropenem
- Where
- Brazil
- Volunteers
- 55 people
- Sponsor
- Beneficência Portuguesa de São Paulo
Bloodstream Infection, Gram Negative Infections
Antibiotic Duration and Outcomes in High-Risk Febrile Neutropenia Patients
The goal of this clinical trial is to learn if a personalized duration of antibiotic therapy, based on clinical stability, is as effective as a standard duration of at least 10 days in hospitalized patients with hematologic…
- Conditions
- Bloodstream Infection, Gram Negative Infections, Bacteraemia Caused by Gram-Negative Bacteria, Febrile Neutropenia (FN)
- Trial name
- PERaSTrA (NCT07372131)
- Testing
- Clinical Stability-Driven Antibiotic Discontinuation Strategy, Standard of Care Antibiotic Duration
- Where
- Italy
- Volunteers
- 172 people
- Sponsor
- Valeria Cento
Pediatric Oncology Patients With Risk for Infections
Swiss 2024 Continous Fever Monitoring in Pediatric Oncology Patients
In children and adolescents undergoing chemotherapy for cancer, fever in neutropenia (FN) is the most frequent potentially lethal complication of chemotherapy for cancer.
- Trial name
- NCT05940766
- Testing
- Automated fever alerts
- Where
- Switzerland
- Volunteers
- 250 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor
Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients
The goal of this clinical trial is to Primary Objectives: 1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during…
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor, Febrile Neutropenia (FN), Myelosuppression Adult
- Trial name
- G-CSF in NHL (NCT06665737)
- Testing
- Early receiving G-CSF group, Late receiving G-CSF group
- Where
- 3 sites in Thailand
- Volunteers
- 126 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN)
Phase II Study of QLC2519 in Pediatric Solid Tumor Participants
QLC2519 (Mai Li Sheng®) is a new protein drug created by fusing the N-terminal of highly active modified G-CSF with the C-terminal of HSA.
- Conditions
- Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN), Neutropenia
- Trial name
- NCT07724756
- Testing
- Albipagrastim alf
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Febrile Neutropenia
Plasma Host-Microbe Proteomics to Predict Complications in High-risk Febrile Neutropenia
Febrile neutropenia (FN) is a common oncologic emergency in patients with hematologic malignancies, associated with high morbidity and mortality.
- Trial name
- NCT07277387
- Testing
- Plasma and DNA sample collection for proteomic and genomic analysis
- Where
- 3 sites in Spain
- Volunteers
- 350 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens
Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
Efbemalenograstim alfa for primary/secondary prevention in patients with solid tumors at high risk for febrile neutropenia (FN) or Intermediate risk of chemotherapy regimens associated with other risk factors in FN
- Conditions
- Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens, Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
- Trial name
- NCT07187908
- Testing
- Efbemalenograstim alfa Injection
- Where
- China
- Volunteers
- 1,076 people
- Sponsor
- Henan Cancer Hospital